NCT01994603

Brief Summary

This trial will pilot test intervention strategies to increase utilization of HIV testing and gain knowledge for designing a clinical trial to evaluate prevention strategies to reduce HIV sexual transmission in the general population in Russia. The study will assess whether external (cost, convenience) or internal factors (low perception of own risk, reluctance to identify a partner as at-risk, fear of stigma) drive Russian women's reluctance to be tested and if peer support impacts their decision. A randomized experimental manipulation, comparing opt-in vs. bundled opt-out testing approaches, followed by focus group discussions, followed by a second-chance testing offer will be used to inform these questions. The answers will enable the international research team to engineer and then test an HIV testing promotion strategy in Russia. The project will collect preliminary data for a larger study to develop an evidence-based program to reduce the HIV transmission in this high risk population.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at below P25 for not_applicable hiv

Timeline
Completed

Started Dec 2012

Typical duration for not_applicable hiv

Geographic Reach
2 countries

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

October 23, 2013

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 26, 2013

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

January 14, 2016

Status Verified

January 1, 2016

Enrollment Period

2.8 years

First QC Date

October 23, 2013

Last Update Submit

January 13, 2016

Conditions

Keywords

PreventionHIVAIDSFetal Alcohol Syndrome (FAS)Alcohol Related Neurodevelopmental Disorder (ARND)

Outcome Measures

Primary Outcomes (2)

  • Number of participants who completed HIV test

    A brief survey completed over the phone. Participants asked when the last HIV test was completed and her reasons for taking the test.

    First 1: at initial contact, an expected average of 15 minutes

  • Number of participants who accepted a rapid health screening/HIV test

    Women's decision to take/not take a health screening test/HIV test is recorded. If a woman chooses to be tested, she will be asked a few questions to assess her reasons for being tested. She will be provided with the results of the testing. If a woman's test is positive for HIV (or other health risks in the bundled opt-out condition), counseling with a trained study nurse, physician or psychologist will be available on-site and a referral for additional testing, counseling, and appropriate medical care will be provided.

    Phase 2: an expected average of 2 hours

Secondary Outcomes (1)

  • Brief survey to assess reasons for being tested

    Phase 2: at time of completing HIV testing

Study Arms (2)

Opt-in testing

EXPERIMENTAL

Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). "There is voluntary HIV testing available to all study participants if you wish to do it. "

Behavioral: Opt-in or Opt-out testingBehavioral: Focus Group

Opt-out testing

EXPERIMENTAL

Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.

Behavioral: Opt-in or Opt-out testingBehavioral: Focus Group

Interventions

Study participants will be offered a health screening onsite.

Opt-in testingOpt-out testing
Focus GroupBEHAVIORAL

Study participants will be invited to participate in a focus group discussion.

Opt-in testingOpt-out testing

Eligibility Criteria

Age18 Years - 44 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • A parent study participants who completed HIV risk survey and
  • Reported two or more partners in the last 12 months and no or inconsistent condom use in the last 3 months and no HIV testing in the last 12 months
  • Or reported any sexually-transmitted disease and no HIV testing in the last 12 months

You may not qualify if:

  • A parent study participants who declined to be contacted for participating in future research studies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States

Location

St. Petersburg State University

Saint Peterburg, 199034, Russia

Location

MeSH Terms

Conditions

Acquired Immunodeficiency SyndromeFetal Alcohol Spectrum Disorders

Interventions

Focus Groups

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesFetal DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesAlcohol-Induced DisordersAlcohol-Related DisordersSubstance-Related DisordersChemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Tatiana Balachova

    University of Oklahoma

    PRINCIPAL INVESTIGATOR
  • Alla Shaboltas, PhD

    Saint Petersburg State University, Russia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2013

First Posted

November 26, 2013

Study Start

December 1, 2012

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

January 14, 2016

Record last verified: 2016-01

Locations